Expert Interview
Discussing the treatment landscape for cervical cancer
Ticker(s): MRK, PFEInstitution: University of Leuven
- Emeritus Professor with Scientific assignment at the Catholic University of Leuven and consultant at the University Hospitals Leuven
- Main areas of clinical and translational research focus on gynecological cancer. He has authored more than 1020 original full papers in peer-reviewed journals.
- Currently Editor of the European Journal of Cancer
What are the different lines of treatment for cervical cancer, and how is Tivdak used in the treatment landscape?
Can you clarify the typical response rate and progression-free survival for second-line patients receiving Tivdak, and what was the control arm in the study?
How tolerable is Tivdak in terms of safety, particularly regarding eye toxicity, and is it being considered for earlier therapy in combination with pembrolizumab?
Added By: slingshot_insightsWhat potential do new therapies such as the Nectin-4 ADC and TROP-2 ADC show in cervical cancer treatment, and how do they compare to existing standards like Tivdak or bevacizumab?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
